TKI(s)	Tyrosine kinase inhibitor(s)
(m)RCC	(Metastatic) renal cell carcinoma
FDA	The Food and Drug Administration
IL-2	Interleukin-2
IFN-α	Interferon alpha
ICIs	Immune checkpoint inhibitors
VEGF(R)	Vascular endothelial growth factor (receptor)
PDGFR	Platelet-derived growth factor receptor
NCCN	National Comprehensive Cancer Network
EMA	The European Medicines Agency
trAEs	Treatment-related adverse events
mTOR	Mammalian target of rapamycin
RANKL	Receptor activator of nuclear factor kappa-beta ligand
BMS	Burning mouth syndrome
(MR)ONJ	(Medication-related) osteonecrosis of the jaw
BID	Twice a day
OD	Once a day
MeSH	Medical Subject Headings
CTCAE	Common Terminology Criteria for Adverse Events